Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,301 to 1,320 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prenatal transplantation of human amniotic fluid stem cell could improve clinical outcome of type III spinal muscular atrophy in mice. | Sci Rep | 2021 | 33911155 | PubTator, text mining | PubMed |
| Gene expression analysis of MCF7 cell lines of breast cancer treated with herbal extract of Cissampelos pareira revealed association with viral diseases. | Gene Rep | 2021 | 33907720 | PubTator, text mining | PubMed |
| Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters. | J Neurol | 2021 | 33899154 | PubTator, text mining | PubMed |
| Label-free quantitative proteomic analysis of extracellular vesicles released from fibroblasts derived from patients with spinal muscular atrophy. | Proteomics | 2021 | 33893753 | PubTator, text mining | PubMed |
| Phenotypes of SMA patients retaining SMN1 with intragenic mutation. | Brain Dev | 2021 | 33892995 | PubTator, text mining | PubMed |
| Emerging role of non-coding RNA in health and disease. | Metab Brain Dis | 2021 | 33881724 | PubTator, text mining | PubMed |
| Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia. | Patient Prefer Adherence | 2021 | 33880016 | PubTator, text mining | PubMed |
| A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. | J Neuromuscul Dis | 2021 | 33867362 | PubTator, text mining | PubMed |
| Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment? | Front Neurol | 2021 | 33854470 | PubTator, text mining | PubMed |
| Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database. | J Neuromuscul Dis | 2021 | 33843692 | PubTator, text mining | PubMed |
| "We needed this": perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. | EClinicalMedicine | 2021 | 33842861 | PubTator, text mining | PubMed |
| Neuropsychiatric Symptoms of COVID-19 Explained by SARS-CoV-2 Proteins' Mimicry of Human Protein Interactions. | Front Hum Neurosci | 2021 | 33833673 | PubTator, text mining | PubMed |
| Small molecule targeting of biologically relevant RNA tertiary and quaternary structures. | Cell Chem Biol | 2021 | 33823146 | PubTator, text mining | PubMed |
| Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future. | Am J Speech Lang Pathol | 2021 | 33822657 | PubTator, text mining | PubMed |
| Use of Intramolecular 1,5-Sulfur-Oxygen and 1,5-Sulfur-Halogen Interactions in the Design of N-Methyl-5-aryl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine SMN2 Splicing Modulators. | J Med Chem | 2021 | 33822618 | PubTator, text mining | PubMed |
| Delivery of oligonucleotide-based therapeutics: challenges and opportunities. | EMBO Mol Med | 2021 | 33821570 | PubTator, text mining | PubMed |
| Revisiting the role of mitochondria in spinal muscular atrophy. | Cell Mol Life Sci | 2021 | 33821292 | PubTator, text mining | PubMed |
| The Limitless Future of RNA Therapeutics. | Front Bioeng Biotechnol | 2021 | 33816449 | PubTator, text mining | PubMed |
Spinal Muscular Atrophy after Nusinersen Therapy: Improved Physiology in Pediatric Patients with No Significant Change in Urine, Serum, and Liquor 1H-NMR Metabolomes in Comparison to an Age-Matched, Healthy Cohort. | Metabolites | 2021 | 33808177 | PubTator, text mining | PubMed |
| Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients. | Brain Sci | 2021 | 33805645 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=66